Burke Whitman Net Worth

The estimated Net Worth of Burke W Whitman is at least $1.17 Millón dollars as of 1 November 2021. Mr. Whitman owns over 1,500 units of Amicus Therapeutics Inc stock worth over $733,474 and over the last 6 years he sold FOLD stock worth over $0. In addition, he makes $433,247 as Independent Director at Amicus Therapeutics Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Whitman FOLD stock SEC Form 4 insiders trading

Burke has made over 36 trades of the Amicus Therapeutics Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he bought 1,500 units of FOLD stock worth $15,735 on 1 November 2021.

The largest trade he's ever made was buying 4,945 units of Amicus Therapeutics Inc stock on 23 August 2019 worth over $49,796. On average, Burke trades about 859 units every 20 days since 2018. As of 1 November 2021 he still owns at least 65,082 units of Amicus Therapeutics Inc stock.

You can see the complete history of Mr. Whitman stock trades at the bottom of the page.

Burke Whitman biography

Burke W. Whitman serves as Independent Director of the Company. Since 2019, he has also served as a member of the Board of Directors of Omega Healthcare Investors (NYSE: OHI) (Audit Committee); member of the Reserve Forces Policy Board (Advisor to the Secretary of Defense); and member of the Board of Trustees of The Lovett School (Atlanta). In business from 1988 to 2008, he served as Chief Executive Officer and initially Chief Operating Officer of Health Management Associates (NYSE: HMA) 2005-08; Chief Financial Officer of Triad Hospitals (NYSE: TRI) 1998-2005; President of Deerfield Healthcare (private) 1994-98; Vice President of Finance of Almost Family (Nasdaq: AFAM) 1992-94; and Investment Banker with Morgan Stanley (NYSE: MS) 1988-92. Concurrently in national service 1985-2019, he served as a reserve officer of the United States Marine Corps, including active duty 1985 to 1988 and 2009 to 2018, where he led five combat deployments, was the Commanding General of 4th Marine Division and Marine Forces Reserve, served with the Secretary of Defense, and retired as a Major General and the Corps’ senior reservist. Mr. Whitman previously served on the Board Directors of the Toys for Tots Foundation (Investment Chair), Board of Directors of the Federation of American Hospitals (Audit Chair), Board of Visitors of Marine Corps University, and Founders Group of the National Museum of the Marine Corps. Mr. Whitman earned a B.A. from Dartmouth College, a Master of Strategic Studies degree from the Army War College, and an M.B.A. from Harvard Business School.

What is the salary of Burke Whitman?

As the Independent Director of Amicus Therapeutics Inc, the total compensation of Burke Whitman at Amicus Therapeutics Inc is $433,247. There are 10 executives at Amicus Therapeutics Inc getting paid more, with John Crowley having the highest compensation of $9,852,660.

How old is Burke Whitman?

Burke Whitman is 64, he's been the Independent Director of Amicus Therapeutics Inc since 2019. There are 1 older and 17 younger executives at Amicus Therapeutics Inc. The oldest executive at Amicus Therapeutics Inc is Robert Essner, 72, who is the Independent Director.

What's Burke Whitman's mailing address?

Burke's mailing address filed with the SEC is 303 International Cir #200, Cockeysville, MD 21030, USA.

Insiders trading at Amicus Therapeutics Inc

Over the last 17 years, insiders at Amicus Therapeutics Inc have traded over $306,740,337 worth of Amicus Therapeutics Inc stock and bought 23,821,602 units worth $176,323,212 . The most active insiders traders include Advisors Llcperceptive Life..., Peter J Barris y Plc Gsk. On average, Amicus Therapeutics Inc executives and independent directors trade stock every 10 days with the average trade being worth of $830,419. The most recent stock trade was executed by Bradley L Campbell on 3 September 2024, trading 7,500 units of FOLD stock currently worth $64,575.

What does Amicus Therapeutics Inc do?

amicus therapeutics is a global, patient-centric biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare metabolic diseases. we have a unique set of platform technologies and medicines in development for patients living with the lysosomal storage disorders fabry disease and pompe disease and we are committed to advancing and expanding a robust pipeline of cutting-edge, first- or best-in-class medicines for these and other rare diseases. the needs of patients in the rare disease community are at the center of our inventive science, our commercial organization, and our clinical programs. our goal throughout all levels of the organization is to make a meaningful difference in the lives of these patients and their caregivers. several opportunities are available to join our team as we build a leading global biotechnology company focused on rare metabolic diseases. our amicus footprint spans 27 countries including our g

Complete history of Mr. Whitman stock trades at Amicus Therapeutics Inc y Omega Healthcare Investors

Amicus Therapeutics Inc executives and stock owners

Amicus Therapeutics Inc executives and other stock owners filed with the SEC include:

• John Crowley,
  Chairman of the Board and Chief Executive Officer
• Bradley Campbell,
  President, Chief Operating Officer, Director
• Ellen Rosenberg,
  General Counsel, Corporate Secretary, Chief Legal Officer
• Hung Do,
  Chief Scientific Officer
• Daphne Quimi,
  Chief Financial Officer
• Jay Barth,
  Chief Medical Officer
• John F. Crowley,
  Chairman & CEO
• Bradley L. Campbell M.B.A.,
  Pres, COO & Director
• Daphne E. Quimi CPA,
  Chief Financial Officer
• Ellen S. Rosenberg,
  Chief Legal Officer & Corp. Sec.
• Burke Whitman,
  Independent Director
• Michael Raab,
  Lead Independent Director
• Glenn Sblendorio,
  Independent Director
• Margaret McGlynn,
  Independent Director
• Lynn Bleil,
  Independent Director
• Craig Wheeler,
  Independent Director
• Robert Essner,
  Independent Director
• David Clark,
  Chief People Officer
• Samantha Prout,
  Principal Accounting Officer, Vice President - Finance, Controller
• Jayne C. Gershkowitz,
  Chief Patient Advocate
• David M. Clark,
  Chief People Officer
• Diana Moore,
  Head of Global Corp. Communications
• Patrik S. Florencio,
  Sr. VP, Global Chief Compliance & Risk Officer
• Andrew Faughnan,
  Sr. Director of Investor Relations
• William D Iii Baird,
  Chief Financial Officer
• Kurt J. Andrews,
  SVP, Human Resources
• Ted W Love,
  Director
• Advisors Llcedelman Josephp...,
  
• Donald J Jr Hayden,
  Director
• Advisors Llcperceptive Life...,
  
• Michael Aaron Kelly,
  
• Group, Llc Green Jeremy Red...,
  
• Sol J Barer,
  Director
• Jayne Gershkowitz,
  VP, Patient Advocacy
• Julie Yu,
  Vice President Clinical Ops
• Kenneth Peist,
  VP, Intellectual Property
• Sinai School Of Medicine Of...,
  10% owner
• David Palling,
  Senior VP, Drug Development
• Orlov S Nicole Schaeffer,
  VP,HR & Leadership Development
• Iv Lpfrazier Healthcare Iv ...,
  
• Pol F Boudes,
  Chief Medical Officer
• Bio Ventures Lp Quaker,
  10% owner
• Mark W Perry,
  10% owner
• David J Lockhart,
  Chief Scientific Officer
• Alexander E Barkas,
  Director
• Enrique Dilone,
  VP, Technical Operations
• Robert E Winkler,
  VP, Clin Research & Operations
• Peter J Barris,
  10% owner
• M James Barrett,
  Director
• Mc Adam M John,
  Corporate Controller
• Iv Lp Frazier Healthcare V,...,
  
• Venture Partners Ii Lpprosp...,
  
• Plc Gsk,
  10% owner
• Matthew R Patterson,
  Chief Operating Officer
• Medical Partners Ii Side Fu...,
  10% owner
• Ken Valenzano,
  VP, Pharmacology & Biology
• Stephen M Bloch,
  Director
• Andrew Shenker,
  VP, Clinical Research
• Allsop David,
  SVP International
• James E Dentzer,
  Chief Financial Officer.
• Gregory M Weinhoff,
  Director
• Geoffrey Gilmore,
  Senior VP, General Counsel
• Iv Lpfrazier Healthcare Iv ...,
  
• Peter M Macaluso,
  VP & Corporate Counsel
• Iv Lpfrazier Healthcare Iv ...,
  
• State Life Sciences Venture...,
  10% owner
• Mark Baldry,
  VP Global Marketing
• James N Topper,
  Director
• Enterprise Associates 11 Lp...,
  
• C Richard Kramlich,
  10% owner
• Charles W Iii Newhall,
  10% owner
• P Sherrill Neff,
  Director
• Gregory P Licholai,
  VP, Medical Affairs
• Iv Lp Frazier Healthcare V,...,
  
• John Kirk,
  VP, Regulatory Affairs
• Dipal Doshi,
  SVP Business Planning & Dev
• Joan Winterbottom,
  SVP, Human Resources
• Medical Partners Ii, L.P. Chl,
  10% owner
• Enterprise Associates 11 Lp...,
  
• Eiry Roberts,
  
• Jeff Castelli,
  Chief Development Officer
• Simon N.R. Harford,
  Chief Financial Officer